Bridging Science and Regulation: BioBoston Consulting’s IND Support for Life Sciences Innovators
Transforming Scientific Innovation into Regulatory Success For biotech and life sciences innovators, advancing a promising therapy from the lab bench to clinical trials demands more than just great science — it requires a strong regulatory strategy and a deep understanding of FDA IND requirements. At BioBoston Consulting, we help emerging biotech companies navigate the Investigational […]
Navigating the Pre-IND Meeting: Strategic FDA Engagement for Biotech Success
For biotech startups and emerging sponsors, the Pre-Investigational New Drug (Pre-IND) meeting is a pivotal opportunity to align with the FDA before launching clinical trials. A well-executed Pre-IND meeting strategy can clarify regulatory expectations, reduce development risks, and accelerate your path to IND submission. But to engage the FDA effectively, preparation must be precise, proactive, […]
CMC in IND Applications: What Biotech Innovators Must Know to Stay FDA-Ready
For biotech companies preparing to file an Investigational New Drug (IND) application, Chemistry, Manufacturing, and Controls (CMC) documentation is a critical pillar of regulatory success. The FDA expects sponsors to demonstrate that their investigational product is manufactured consistently, safely, and in compliance with Good Manufacturing Practice (GMP). A strong CMC strategy not only supports IND […]